Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma
Journal of Clinical Oncology, 09/28/09

Newton-Bishop JA et al. – Results from the retrospective study were consistent with a role for vitamin D in melanoma outcome. The cohort study tests this hypothesis, providing evidence that higher 25-hydroxyvitamin D3 levels, at diagnosis, are associated with both thinner tumors and better survival from melanoma, independent of Breslow thickness. Patients with melanoma, and those at high risk of melanoma, should seek to ensure vitamin D sufficiency.

Methods

Pilot retrospective study of 271 patients with melanoma suggested that vitamin D may protect against recurrence of melanoma
These findings tested in survival analysis in cohort of 872 patients recruited to Leeds Melanoma Cohort (median follow-up, 4.7 years)

Results

Self-reports of taking vitamin D supplements were nonsignificantly correlated with reduced risk of melanoma relapse (odds ratio = 0.6; 95% CI, 0.4 to 1.1)
Nonrelapsers had higher mean 25-hydroxyvitamin D3 levels than relapsers (49 v 46 nmol/L; not statistically significant)
In the cohort (prospective) study, higher 25-hydroxyvitamin D3 levels were associated with lower Breslow thickness at diagnosis and were independently protective of relapse and death
Hazard ratio for RFS was 0.79 (95% CI, 0.64 to 0.96) for a 20 nmol/L increase in serum level
Evidence of interaction between the vitamin D receptor (VDR) BsmI genotype and serum 25-hydroxyvitamin D3 levels on RFS

<< Previous
Primary testicular diffuse large B-cell lymphoma: a...

Next >>
Preoperative multimodality therapy improves disease-free survival...